HIV, mRNA vaccine study by Iavi and Moderna
First doses have already been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU), School of Medicine and Health Sciences in Washington DC
IAVI and Modern’s HIV vaccine
IAVI, the non-profit scientific research organisation, and the biotechnology company Moderna are launching a trial of HIV vaccine antigens provided by mRNA technology.
The first doses have already been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU), School of Medicine and Health Sciences in Washington DC.
The phase 1 study, IAVI G002, is designed to test the hypothesis that sequential administration of first doses and booster doses of HIV immunogens delivered by messenger RNA (mRNA) can induce specific classes of B-cell responses and drive their early maturation towards the development of broadly neutralising antibodies (bnAb).
The induction of bnAbs is widely regarded as a goal of the HIV vaccine, and this is the first step in that process
The study will be tested on 56 healthy, HIV-negative adult volunteers.
Forty-eight participants will receive one or two doses of eOD-GT8 60mer mRNA Vaccine (mRNA-1644), with 32 of them receiving the Core-g28v2 60mer mRNA Vaccine boost (mRNA-1644v2-Core).
Another eight volunteers will receive the boost immunogen alone.
Participants will be monitored for six months after the last vaccination.
IAVI and Moderna assure that the immune responses of the vaccine participants will be examined in molecular detail to assess whether the response targets have been met.
Read Also:
Sanofi Pasteur Study Shows Efficacy Of Co-Administration Of Covid And Influenza Vaccines
WHO: ‘Pandemic Will Continue Unless Vaccines Are Distributed To Poor Countries’
Covid And HIV: ‘Monoclonal Antibodies For The Cures Of The Future’